Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268031 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL1648522 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL15566127 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL5251441 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL8960305 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL9073605 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL6384775 | 0.94 | MEN1 (0.53) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL7515687 | 0.94 | PLA2G1B (0.49) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL9005240 | 0.92 | LMNA (0.46) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL18554720 | 0.92 | LMNA (0.46) | LMNAESR1ADORA3CDC25AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115032286-A | Application of composition in preparation of medicine for diagnosing infantile hemangioma and/or monitoring progression and prognosis of infantile hemangioma, kit and medicine | 江成鸿 | 2022-09-09 | — | — | CN | claimed |
| WO-2017178954-A1 | NANOBUBBLES AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2017-10-19 | — | — | WO | claimed |
| EP-2547342-A2 | COMBINED USE OF PHOSPHOLIPID AND SULFATE GROUPS-CARRYING POLYSACCHARIDES FOR INHIBITING METASTATIC SPREAD | KTB Tumorforschungsgesellschaft mbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113892-A2 | COMBINED USE OF PHOSPHOLIPID AND SULFATE GROUPS-CARRYING POLYSACCHARIDES FOR INHIBITING METASTATIC SPREAD | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2011-09-22 | — | — | WO | claimed |
| EP-1315506-A4 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | DPHARM LTD (IL) | 2005-03-30 | — | — | EP | claimed |
| WO-2003057190-A1 | EFFICIENT NUCLEIC ACID ENCAPSULATION INTO MEDIUM SIZED LIPOSOMES | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1315506-A2 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | D-Pharm Ltd (IL) | 2003-06-04 | — | — | EP | claimed |
| WO-2002007669-A2 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | D-PHARM LTD. (IL) | 2002-01-31 | — | — | WO | claimed |
| US-20250319025-A9 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4590821-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR MODULATING T CELL FUNCTION | Tune Therapeutics, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4573200-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | Tune Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4568940-A2 | SULFUR-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF FOR DELIVERY OF NUCLEIC ACIDS | Poseida Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-120051297-A | Combination of engineered Natural Killer (NK) cells and antibody therapies and related methods | 因达普塔治疗公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4554967-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TARGETED TRANSCRIPTIONAL ACTIVATION | Tune Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2002007669-A2 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | D-PHARM LTD. (IL) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001055166-A1 | CLONED HUMAN LYSOPHOSPHOLIPASE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0726761-A1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOTECH MEDICAL, INC. (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012385-A1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOTECH MEDICAL, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1993015722-A1 | CONTROLLED DELIVERY OF PHARMACEUTICALS FROM PREFORMED POROUS MICROPARTICLES | SYNTEX (USA) INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0440742-A1 | LIPOSOME IMMUNOADJUVANTS CONTAINING IL-2. | UNIV MINNESOTA (US) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319025-A9 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | PHOSPHO1, SGMS1, LIPA | LMNA 275/4885ESR1 4774/4885ADORA3 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.